Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT05039450 is registered in ClinicalTrials.gov with Akero Therapeutics, Inc as lead sponsor.

NCT NCT05039450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05039450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Akero Therapeutics, Inc
Phase
Phase 2
Overall status
Completed
Start date
July 30, 2021
Completion date
August 28, 2025
Enrollment
213 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis